Super underrated 💎-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

Super underrated 💎

BRIEF-Neurosense Reports Additional Positive Results From ALS Phase 2B Trial

Feb 21 - Neurosense Therapeutics Ltd : * NEUROSENSE REPORTS ADDITIONAL POSITIVE RESULTS FROM ITS ALS PHASE 2B PARADIGM TRIAL * NEUROSENSE THERAPEUTICS LTD - PRIMEC DEMONSTRATED A CLINICALLY MEANINGFUL EFFECT ON QUALITY OF LIFE AND ON COMPLICATION FREE-SURVIVAL FOR PATIENTS WITH ALS * NEUROSENSE THERAPEUTICS LTD - FURTHER ANALYSIS OF PARADIGM IS ON TRACK WITH NEUROFILAMENT RESULTS EXPECTED IN Q1 * NEUROSENSE THERAPEUTICS LTD - TDP-43 AND PROSTAGLANDINJ2 BIOMARKERS EXPECTED IN FIRST HALF OF 2024 * NEUROSENSE THERAPEUTICS - STANDARD ALS MEASURE ALSFRS-R ALREADY SHOWED STATISTICALLY SIGNIFICANT EFFECT OF PRIMEC ON SLOWING DOWN DISEASE PROGRESSIONSource text for Eikon: Further company coverage:

BRIEF-Neurosense Reports Additional Positive Results From ALS Phase 2B Trial

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":291364334825688,"tweetId":"291364334825688","gmtCreate":1712159789193,"gmtModify":1712159792849,"author":{"id":4105164288302490,"idStr":"4105164288302490","authorId":4105164288302490,"authorIdStr":"4105164288302490","name":"Sky Tgr","avatar":"https://static.itradeup.com/news/2df38375a020643507d69e511e3afc6b","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":1,"individualDisplayBadges":[],"fanSize":8,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>Super underrated 💎&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Super underrated 💎&nbsp;</p></body></html>","text":"Super underrated 💎","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/291364334825688","repostId":2413426081,"repostType":2,"repost":{"id":"2413426081","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1708522740,"share":"https://www.laohu8.com/m/news/2413426081?lang=&edition=full","pubTime":"2024-02-21 21:39","market":"us","language":"en","title":"BRIEF-Neurosense Reports Additional Positive Results From ALS Phase 2B Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2413426081","media":"Reuters","summary":"Feb 21  - Neurosense Therapeutics Ltd   :   * NEUROSENSE REPORTS ADDITIONAL POSITIVE RESULTS FROM ITS ALS PHASE 2B PARADIGM TRIAL   * NEUROSENSE THERAPEUTICS LTD - PRIMEC DEMONSTRATED A CLINICALLY MEANINGFUL EFFECT ON QUALITY OF LIFE AND ON COMPLICATION FREE-SURVIVAL FOR PATIENTS WITH ALS   * NEUROSENSE THERAPEUTICS LTD - FURTHER ANALYSIS OF PARADIGM IS ON TRACK WITH NEUROFILAMENT RESULTS EXPECTED IN Q1   * NEUROSENSE THERAPEUTICS LTD - TDP-43 AND PROSTAGLANDINJ2 BIOMARKERS EXPECTED IN FIRST HALF OF 2024   * NEUROSENSE THERAPEUTICS - STANDARD ALS MEASURE ALSFRS-R ALREADY SHOWED STATISTICALLY SIGNIFICANT EFFECT OF PRIMEC ON SLOWING DOWN DISEASE PROGRESSIONSource text for Eikon:    Further company coverage:    ","content":"<html><body><p>Feb 21 (Reuters) - <a href=\"https://laohu8.com/S/NRSN\">Neurosense Therapeutics Ltd</a>   :</p><p>   * NEUROSENSE REPORTS ADDITIONAL POSITIVE RESULTS FROM ITS ALS PHASE 2B PARADIGM TRIAL</p><p>   * NEUROSENSE THERAPEUTICS LTD - PRIMEC DEMONSTRATED A CLINICALLY MEANINGFUL EFFECT ON QUALITY OF LIFE AND ON COMPLICATION FREE-SURVIVAL FOR PATIENTS WITH ALS</p><p>   * NEUROSENSE THERAPEUTICS LTD - FURTHER ANALYSIS OF PARADIGM IS ON TRACK WITH NEUROFILAMENT RESULTS EXPECTED IN Q1</p><p>   * NEUROSENSE THERAPEUTICS LTD - TDP-43 AND PROSTAGLANDINJ2 BIOMARKERS EXPECTED IN FIRST HALF OF 2024</p><p>   * NEUROSENSE THERAPEUTICS - STANDARD ALS MEASURE ALSFRS-R ALREADY SHOWED STATISTICALLY SIGNIFICANT EFFECT OF PRIMEC ON SLOWING DOWN DISEASE PROGRESSION</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Neurosense Reports Additional Positive Results From ALS Phase 2B Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Neurosense Reports Additional Positive Results From ALS Phase 2B Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-02-21 21:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Feb 21 (Reuters) - <a href=\"https://laohu8.com/S/NRSN\">Neurosense Therapeutics Ltd</a>   :</p><p>   * NEUROSENSE REPORTS ADDITIONAL POSITIVE RESULTS FROM ITS ALS PHASE 2B PARADIGM TRIAL</p><p>   * NEUROSENSE THERAPEUTICS LTD - PRIMEC DEMONSTRATED A CLINICALLY MEANINGFUL EFFECT ON QUALITY OF LIFE AND ON COMPLICATION FREE-SURVIVAL FOR PATIENTS WITH ALS</p><p>   * NEUROSENSE THERAPEUTICS LTD - FURTHER ANALYSIS OF PARADIGM IS ON TRACK WITH NEUROFILAMENT RESULTS EXPECTED IN Q1</p><p>   * NEUROSENSE THERAPEUTICS LTD - TDP-43 AND PROSTAGLANDINJ2 BIOMARKERS EXPECTED IN FIRST HALF OF 2024</p><p>   * NEUROSENSE THERAPEUTICS - STANDARD ALS MEASURE ALSFRS-R ALREADY SHOWED STATISTICALLY SIGNIFICANT EFFECT OF PRIMEC ON SLOWING DOWN DISEASE PROGRESSION</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1861220033.SGD":"Blackrock Next Generation Technology A2 SGD-H","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","NRSN":"Neurosense Therapeutics Ltd","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU1861215975.USD":"贝莱德新一代科技基金 A2","BK4139":"生物科技","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU1548497426.USD":"安联环球人工智能AT Acc","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","ON":"安森美半导体","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","BK4512":"苹果概念","BK4141":"半导体产品"},"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2413426081","content_text":"Feb 21 (Reuters) - Neurosense Therapeutics Ltd   :   * NEUROSENSE REPORTS ADDITIONAL POSITIVE RESULTS FROM ITS ALS PHASE 2B PARADIGM TRIAL   * NEUROSENSE THERAPEUTICS LTD - PRIMEC DEMONSTRATED A CLINICALLY MEANINGFUL EFFECT ON QUALITY OF LIFE AND ON COMPLICATION FREE-SURVIVAL FOR PATIENTS WITH ALS   * NEUROSENSE THERAPEUTICS LTD - FURTHER ANALYSIS OF PARADIGM IS ON TRACK WITH NEUROFILAMENT RESULTS EXPECTED IN Q1   * NEUROSENSE THERAPEUTICS LTD - TDP-43 AND PROSTAGLANDINJ2 BIOMARKERS EXPECTED IN FIRST HALF OF 2024   * NEUROSENSE THERAPEUTICS - STANDARD ALS MEASURE ALSFRS-R ALREADY SHOWED STATISTICALLY SIGNIFICANT EFFECT OF PRIMEC ON SLOWING DOWN DISEASE PROGRESSIONSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","news_type":1},"isVote":1,"tweetType":1,"viewCount":238,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":17,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}